Alnylam Pharmaceuticals, Inc. (ALNY) is listed on NASDAQ in Pharmaceutical Stocks. It is $236.99, +0.18%, with a $31.7B market cap. RSI is 45.2, neutral. The latest reported quarter missed estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 45.2 Neutral
Market Cap $31.7B
Volume 1.9M
Fundamentals — 10-Q Q2 2026
Revenue $2.5B
Net Income $370.5M
EPS $2.71
Gross Margin 79.4%
Operating Margin 20.3%
Net Margin 15.1%
P/E Ratio 87.5x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Pyott David E I | Director | Sell | 3,830 | $299.18 | $1.1M | 2026 Jun 1 |
| McLaughlin Melissa | Chief Human Resources Officer | Sell | 3,910 | $325.92 | $1.3M | 2026 Apr 6 |
| Garg Pushkal | EVP Chief R&D | Sell | 4,713 | $323.53 | $1.5M | 2026 Mar 5 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 1,291 | $323.54 | $417,685 | 2026 Mar 5 |
| Greenstreet Yvonne | Chief Executive Officer | Sell | 2,933 | $323.08 | $947,581 | 2026 Mar 4 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 2,468 | $323.08 | $797,351 | 2026 Mar 4 |
| Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 2,309 | $323.08 | $745,984 | 2026 Mar 4 |
| Garg Pushkal | EVP Chief R&D | Sell | 3,492 | $323.63 | $1.1M | 2026 Mar 3 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 3,250 | $323.62 | $1.1M | 2026 Mar 3 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 2,206 | $327.65 | $722,801 | 2026 Mar 2 |
| Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 1,598 | $327.65 | $523,584 | 2026 Mar 2 |
| Greenstreet Yvonne | Chief Executive Officer | Sell | 6,799 | $327.65 | $2.2M | 2026 Mar 2 |
| Garg Pushkal | EVP Chief R&D | Sell | 4,627 | $331.34 | $1.5M | 2026 Feb 27 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 12,128 | $452.18 | $5.5M | 2025 Nov 17 |
| Greenstreet Yvonne | Chief Executive Officer | Sell | 25,650 | $452.75 | $11.6M | 2025 Nov 13 |
| Garg Pushkal | EVP Chief R&D | Sell | 5,959 | $451.76 | $2.7M | 2025 Oct 3 |
| Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 1,405 | $452.05 | $635,126 | 2025 Oct 2 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 3,821 | $452.05 | $1.7M | 2025 Oct 2 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 2,441 | $452.05 | $1.1M | 2025 Oct 2 |
| Greenstreet Yvonne | Chief Executive Officer | Sell | 8,924 | $452.05 | $4.0M | 2025 Oct 2 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $515.52 | 46.7 | $22.1B |
| | $77.31 | 53.6 | $31.9B |
| | $153.79 | 49.7 | -- |
| | $66.58 | 60.7 | $136.0B |
| | $36.44 | 58.3 | $42.5B |
Take ALNY further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put ALNY in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Alnylam Pharmaceuticals, Inc. next reports.
Set alerts on ALNY
Get notified when Alnylam Pharmaceuticals, Inc. hits your price targets or technical conditions are met.
Get Started Free